StockNews.com started coverage on shares of Agile Therapeutics (NASDAQ:AGRX – Free Report) in a research note published on Friday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Agile Therapeutics Price Performance
Shares of AGRX opened at $1.47 on Friday. The company’s 50-day moving average is $0.96 and its 200-day moving average is $0.82. Agile Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $2.88.
Agile Therapeutics (NASDAQ:AGRX – Get Free Report) last released its quarterly earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.63) EPS for the quarter. The company had revenue of $5.72 million for the quarter.
Institutional Investors Weigh In On Agile Therapeutics
Agile Therapeutics Company Profile
Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
Further Reading
- Five stocks we like better than Agile Therapeutics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- 3 Fintech Stocks With Good 2021 Prospects
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Are Penny Stocks a Good Fit for Your Portfolio?
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.